IT 103Alternative Names: IT103
Latest Information Update: 28 Nov 2016
At a glance
- Originator IthenaPharma
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Inflammation
Most Recent Events
- 16 Nov 2016 IthenaPharma has been acquired by Marina Biotech
- 13 Sep 2016 Clinical trials in Inflammation in USA (unspecified route) before September 2016